Riabni savings card: as little as $0 a dose with commercial insurance

Riabni is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Riabni is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameRiabni

Authorized genericrituximab-arrx

Regular genericrituximab-arrx

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Riabni?

The original

–

Brand nameThe maker’s card

Amgen SupportPlus Co-Pay Program

Savings card from Amgen

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a dose

Or call 1-866-264-2778.

In the maker’s words

“Pay as little as $0 out-of-pocket for each dose…”

From the maker’s offer on riabni.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Riabni itself, from the same company, sold without the brand name, and usually for less. For now Riabni is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Riabni is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of:

Adult patients with Non-Hodgkin's Lymphoma (NHL).
- Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Adult patients with Chronic Lymphocytic Leukemia (CLL).
- Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies.
Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids.
Moderate to severe Pemphigus Vulgaris (PV) in adult patients.

Source: the FDA label for Riabni (Amgen, Inc), October 1, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/riabni/